Fabienne Thomas

Toulouse, France

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 68 publications

Does Next Generation Sequencing (NGS)-Based CYP2D6 Sequencing Improve Genotype-Phenotype Concordance in Tamoxifen-Treated Patients?

Does Next Generation Sequencing (NGS)-Based CYP2D6 Sequencing Improve Genotype-Phenotype Concordance in Tamoxifen-Treated Patients?

Journal: Clinical pharmacology and therapeutics
Published: February 12, 2026

Correction: Exposure-response relationship of cabozantinib in patients with metastatic renal cell carcinoma treated in routine care.

Correction: Exposure-response relationship of cabozantinib in patients with metastatic renal cell carcinoma treated in routine care.

Journal: British journal of cancer
Published: January 20, 2026

A multi-ancestry genome-wide study of tamoxifen metabolism and breast cancer recurrence.

A multi-ancestry genome-wide study of tamoxifen metabolism and breast cancer recurrence.

Journal: NPJ breast cancer
Published: December 03, 2025

Model-Informed Precision Dosing of Protein Kinase Inhibitors: Evaluation of Model-Averaging and Flattened Priors Methods.

Model-Informed Precision Dosing of Protein Kinase Inhibitors: Evaluation of Model-Averaging and Flattened Priors Methods.

Journal: Clinical pharmacokinetics
Published: October 29, 2025

Phase I/II Study of the PARP Inhibitor Olaparib and Irinotecan in Children and Young Adults with Recurrent/Refractory Malignancies: Arm D of the AcSé-ESMART Trial.

Phase I/II Study of the PARP Inhibitor Olaparib and Irinotecan in Children and Young Adults with Recurrent/Refractory Malignancies: Arm D of the AcSé-ESMART Trial.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: October 08, 2025

Benefit of plasma cystatin C for carboplatin individual dosing in a patient with spinal amyotrophy.

Benefit of plasma cystatin C for carboplatin individual dosing in a patient with spinal amyotrophy.

Journal: Cancer chemotherapy and pharmacology
Published: September 22, 2025

The variant c.2766+3A>T in DPYD leads to exon 21 skipping and is associated with DPD deficiency and severe fluoropyrimidine toxicity.

The variant c.2766+3A>T in DPYD leads to exon 21 skipping and is associated with DPD deficiency and severe fluoropyrimidine toxicity.

Journal: British journal of clinical pharmacology
Published: August 18, 2025

French-Speaking Network of Pharmacogenetics (RNPGx) Recommendations for Gene Panel Analysis Through Genotyping or Sequencing in Pharmacogenetics.

French-Speaking Network of Pharmacogenetics (RNPGx) Recommendations for Gene Panel Analysis Through Genotyping or Sequencing in Pharmacogenetics.

Journal: Fundamental & clinical pharmacology
Published: June 23, 2025

Tumor-associated macrophages confer resistance to chemotherapy (Trifluridine/Tipiracil) in digestive cancers by overexpressing thymidine phosphorylase.

Tumor-associated macrophages confer resistance to chemotherapy (Trifluridine/Tipiracil) in digestive cancers by overexpressing thymidine phosphorylase.

Journal: Cancer letters
Published: September 18, 2024

Metabolic reprogramming of hypoxic tumor-associated macrophages through CSF-1R targeting favors treatment efficiency in colorectal cancers.

Metabolic reprogramming of hypoxic tumor-associated macrophages through CSF-1R targeting favors treatment efficiency in colorectal cancers.

Journal: Journal for immunotherapy of cancer
Published: September 09, 2024

Reply to: "Is uracil enough for effective pre-emptive DPD testing?"

Reply to: "Is uracil enough for effective pre-emptive DPD testing?"

Journal: Clinical chemistry and laboratory medicine
Published: August 02, 2024

Therapeutic Drug Monitoring of Imatinib: Is There a Rationale for Also Quantifying Its Active Metabolite?

Therapeutic Drug Monitoring of Imatinib: Is There a Rationale for Also Quantifying Its Active Metabolite?

Journal: Chemotherapy
Published: July 30, 2024
Showing 1-12 of 68

Last Updated: 09/26/2026